SCHEMBL1092652

SCHEMBL1092652

CON(C)C(=O)c1cccnc1O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 2/20 0.42
NAPRT Q6XQN6 2/20 0.40
POLB P06746 1/20 0.38
KDM4E B2RXH2 3/20 0.38
TDP1 Q9NUW8 2/20 0.38
HCRTR1 O43613 1/20 0.37
HCRTR2 O43614 1/20 0.37
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
BLM P54132 1/20 0.37
AGER Q15109 1/20 0.37
LMNA P02545 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
P2RX7 Q99572 1/20 0.36
MAP2K1 Q02750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL307472 0.83 P2RX7 (0.50) TRPM8NAPRTPOLBKDM4ETDP1
SCHEMBL781008 0.83 NAPRT (0.56) TRPM8NAPRTPOLBKDM4ETDP1
SCHEMBL29999839 0.82 TRIM24 (0.40) TRPM8NAPRTPOLBKDM4ETDP1
SCHEMBL257468 0.82 LMNA (0.54) POLBTDP1L3MBTL1LMNASMN1; SMN2
SCHEMBL16345329 0.82 TRIM24 (0.40) TRPM8NAPRTPOLBKDM4ETDP1
SCHEMBL306737 0.82 POLB (0.45) NAPRTPOLBTDP1HCRTR1HCRTR2
SCHEMBL29865799 0.82 LMNA (0.54) POLBTDP1L3MBTL1LMNASMN1; SMN2
SCHEMBL3922378 0.80 PARP1 (0.55) POLBKDM4ETDP1ALDH1A1L3MBTL1
SCHEMBL1447353 0.78 HCRTR1 (0.45) NAPRTKDM4ETDP1HCRTR1HCRTR2
SCHEMBL25298982 0.77 MLYCD (0.40) NAPRTKDM4ETDP1HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024215863-A2 INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) PSY THERAPEUTICS, INC. (US) 2024-10-17 WO disclosed
US-8153634-B2 Carbinol derivatives having cyclic linker KOWA COMPANY, LTD. (JP) 2012-04-10 US disclosed
EP-2281817-A1 SUBSTITUTED CARBINOL COMPOUND HAVING CYCLIC LINKER Kowa Company, Ltd. (JP) 2011-02-09 EP disclosed
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER KOWA COMPANY, LTD. (JP) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048610-A1 CARBINOL DERIVATIVES HAVING CYCLIC LINKER NR1H2, NR1H3, LDLR TRPM8 1823/4885NAPRT 1374/4885POLB 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.